OxCD3: Oxford Centre for Drug Delivery Devices

OxCD3：牛津药物输送设备中心

• 批准号: EP/L024012/1
• 负责人: Constantin Coussios
• 金额: $ 815.26万
• 依托单位: University of Oxford
• 依托单位国家: 英国
• 项目类别: Research Grant
• 财政年份: 2014
• 资助国家: 英国
• 起止时间: 2014 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=EP%2FL024012%2F1
• 关键词: OxCD3; Oxford; Centre; Drug; Delivery

The greatest challenge in oncological drug delivery is achieving successful penetration and distribution of the therapeutic agent throughout the tumour: billions of pounds have been spent to date in deploying biochemical approaches in an attempt to solve what is essentially an engineering problem, namely the transport of therapeutics from the blood stream to reach every cancer cell. OxCD3 will seek to transform both clinical and industry practice in drug delivery by demonstrating the value and feasibility of engineering approaches, involving a combination of stimulus-responsive nanocarriers and medical devices already in clinical use, for improved tumour uptake and therapeutic outcome. The Programme Grant will enable the creation of a sustainable, world-unique multi-disciplinary environment for combinational engineering of biology, chemistry and medical devices to improve drug delivery under a single roof. It is also expected to create a unique training environment for the next generation of young scientists working on combination therapies and biomedical nanotechnology, by providing direct exposure to regulatory and manufacturing issues encountered when translating laboratory research into production and clinical practice. A unique feature of the Centre is the capability to design both devices and drug delivery vehicles under a single roof. In the first 5 years, under EPSRC funding, up to 3 carefully selected "Device+Drug" exemplars will be manufactured to GMP, ready for Phase I clinical trials, to provide compelling evidence of feasibility to industrial partners and clinicians; in the next 5 years, a private-public partnership will be built to complete clinical trials of these exemplars using therapeutics of strategic significance to the pharmaceutical industry; beyond 10 years, full industrial sponsorship of the OXCD3 is anticipated, which will focus on addressing next-generation challenges in drug delivery (beyond cancer) in partnership with industry and clinicians. The transformative aim over 50 years is to position the UK as the world leader for multi-disciplinary drug delivery development, complementing its existing position as a drug discovery leader, from design to manufacture and clinical trials.

肿瘤药物递送的最大挑战是实现治疗剂在整个肿瘤中的成功渗透和分布：迄今为止，已经花费了数十亿英镑用于部署生化方法，试图解决本质上是工程问题的问题，即治疗剂从血流中运输到每个癌细胞。OxCD 3将通过展示工程方法的价值和可行性，寻求改变药物输送的临床和行业实践，涉及刺激响应纳米载体和已在临床使用的医疗设备的组合，以改善肿瘤吸收和治疗效果。该计划赠款将为生物学，化学和医疗器械的组合工程创造一个可持续的，世界独特的多学科环境，以改善单一屋顶下的药物输送。它还有望为下一代从事组合疗法和生物医学纳米技术的年轻科学家创造一个独特的培训环境，通过直接接触将实验室研究转化为生产和临床实践时遇到的监管和制造问题。该中心的一个独特之处是能够在一个屋檐下设计装置和药物运送车辆。在前5年，在EPSRC的资助下，最多3个精心挑选的“器械+药物”样本将按照GMP生产，准备进行I期临床试验，为工业合作伙伴和临床医生提供令人信服的可行性证据;在未来5年，将建立公私合作伙伴关系，使用对制药行业具有战略意义的治疗方法完成这些样本的临床试验;在10年之后，预计OXCD 3将得到全面的工业赞助，重点是与工业界和临床医生合作解决下一代药物输送（癌症以外）的挑战。50年来的变革目标是将英国定位为多学科药物递送开发的世界领导者，补充其作为药物发现领导者的现有地位，从设计到制造和临床试验。

项目成果

Subcellular Targeting of Theranostic Radionuclides.

• DOI: 10.3389/fphar.2018.00996
• 发表时间: 2018
• 期刊: Frontiers in pharmacology
• 影响因子: 5.6
• 作者: Bavelaar BM;Lee BQ;Gill MR;Falzone N;Vallis KA
• 通讯作者: Vallis KA

Expanding the chemical functionality of DNA nanomaterials generated by rolling circle amplification.

• DOI: 10.1093/nar/gkab720
• 发表时间: 2021-09-20
• 期刊: Nucleic acids research
• 影响因子: 14.9
• 作者: Baker YR;Yuan L;Chen J;Belle R;Carlisle R;El-Sagheer AH;Brown T
• 通讯作者: Brown T

A Combined Magnetic-Acoustic Device for Simultaneous, Coaligned Application of Magnetic and Ultrasonic Fields

• DOI: 10.1002/admt.201800081
• 发表时间: 2018-07-01
• 期刊: ADVANCED MATERIALS TECHNOLOGIES
• 影响因子: 6.8
• 作者: Barnsley, Lester C.;Gray, Michael D.;Stride, Eleanor
• 通讯作者: Stride, Eleanor